KRAS and thyroid gland carcinoma: In particular, we selected thyroid cancer-derived cell lines (B-CPAP and 8505C) harbouring BRAF V600E, the SV40-immortalized thyrocyte cell line (Nthy-ori-3-1), NSCLC cell lines (A549, PC-9 and Calu-1) harbouring KRAS G12S, HER1 LREA del and KRAS G12C, respectively, and the CRC cell line (HCT-116) harbouring KRAS G38A.